Posted: 24 October 2025
A world-first AI-powered disease progression model for facioscapulohumeral muscular dystrophy (FSHD) has been developed through a collaboration between Swinburne University of Technology, the FSHD Global Research Foundation, the National Imaging Facility (NIF), and Springbok Analytics, marking a milestone in the application of digital health technologies to rare disease management and precision medicine.
The model combines whole-body MRI data from 50 Australian patients with international datasets to map and predict the progression of FSHD – an inherited condition causing progressive muscle weakening that affects both adults and children. Using Swinburne Neuroimaging’s advanced MRI capabilities, the initiative is generating unprecedented insights into muscle composition and asymmetry, helping clinicians quantify disease impact in ways previously unattainable.
FSHD Global Research Foundation Managing Director, Emma Weatherley, who lives with FSHD, said the project was redefining how muscle disease is monitored.
“Patients can see their muscle health in three dimensions and track how the disease progresses over time,” she said. “This pilot project is not just a milestone for FSHD research in Australia but a beacon of hope for everyone affected by muscle disease.”
The project underscores the convergence of AI, medical imaging, and data analytics in creating actionable health insights. Springbok Analytics’ machine learning platform enables quantitative assessment of muscle health, providing clinicians and researchers with 3D visualisations that can inform targeted interventions, accelerate therapeutic trials, and improve patient outcomes.
Dr David White, Director of Swinburne Neuroimaging, said the collaboration exemplified how translational research infrastructure can drive clinical innovation.
“By harnessing cutting-edge whole-body imaging and AI technology, we are poised to make substantial advances in medical research and offer much-needed insight for patients,” he said.
The data collected will also help establish a national MRI standard for muscular dystrophy, supported by the NIF network. NIF Chief Executive Officer Professor Wojtek Goscinski noted that such standardisation would strengthen Australia’s capability in advanced imaging and multi-site research collaborations.
By integrating digital imaging, predictive modelling, and patient-derived data, this initiative highlights the growing role of AI-enabled health technologies in supporting evidence-based, personalised care for complex conditions like FSHD.
Find out more here.
